Hyperparathyroidism Treatment: Observation, Medication, Surgery, and Emerging Options

Primary hyperparathyroidism (PHPT) management depends on severity, symptoms, age, and guidelines (AAES/ACE, NICE).

1. Observation (Asymptomatic, Mild)

• Criteria: Calcium <1 mg/dL above upper limit, no osteoporosis, no stones, normal renal function, age >50 (some guidelines).
• Monitor: serum calcium, PTH, creatinine, DXA (spine/hip/forearm), renal imaging q1–2y.

2. Medical Management (Non-Surgical Candidates)

• Cinacalcet (calcimimetic): Lowers PTH and calcium; does not improve bone density. Used if surgery contraindicated.
• Bisphosphonates / Denosumab: Improve BMD; do not lower calcium/PTH. Adjunctive.
• HRT / SERMs: Historical; not first-line.

3. Surgery (Parathyroidectomy) — Definitive Cure

• Indications: Symptomatic; calcium >1 above ULN; osteoporosis (T-score ≤-2.5 or fracture); age <50; stones; nephrocalcinosis; patient preference.
• Approach: Minimally invasive (focused) if preoperative imaging (sestamibi, US, 4D-CT) localizes single adenoma (85%). Bilateral exploration if not localized or multigland disease.
• Outcomes: Cure rate >95% (experienced surgeons). Transient hypocalcemia common (hungry bone); permanent hypoparathyroidism <1–2%.

4. Other Modalities

• Radiation therapy: Not standard; historical for inoperable.
• Dialysis: For ESRD with tertiary HPT; not for PHPT.

Decision Framework

Shared decision-making: surgery offers cure; medical management controls biochemistry but not disease. Age <50 strongly favors surgery.